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The mostly unmet need as well as the pressure to show efficacy of new 
therapies to treat rare diseases contrasts with the limited possibility to use 
traditional statistical methods to design and analyse clinical trials in this setting. 
Within this paper, we will refer to the current state of design and analysis 
methods, as well as practical conditions to be considered when conducting a 
clinical trial for rare diseases. We will embed the research of the IDeAl project 
within this setting and give some first recommendations to improve the 
methodology for clinical trials in rare diseases.
Introduction
Common to the definition of rare diseases is the relative frequency 
of the number of affected patients in the parent population. Thus, 
a disease is considered as rare if fewer than 1 out of 2000 in the 
EU, 1500 in the US and 2500 in Japan are affected. The number of 
rare diseases is estimated to be 6‐80001. However, for some rare 
diseases it is not difficult to prove the efficacy of a new treatment, 
because the population size is relatively large. For instance the 
incidence of Friedreich Ataxia in the general population is roughly 
1 of 50,000 resulting in 10,000 new patients in the EU. However 
the majority of rare diseases are less frequent2. Most of the diseases 
cannot be treated adequately. Consequently the International Rare 
Disease Research Consortium has stated the objective to make the 
diagnosis of as many rare diseases as possible and to contribute to 
the development of 200 new rare disease treatments by 20203.
The problem with drug approval in rare diseases is among others 
related to the limited evidence resulting from clinical trials in small 
populations. The methodological framework on clinical trials in 
small populations from the regulator perspective is described in the 
EU by the EMA guidance4 and in the US by the draft guidance on 
rare disease5. The framework covers aspects like levels of evidence, 
pharmacological considerations, choice of endpoints and control 
group as well as methodological and statistical considerations. 
Especially with respect to paediatric trials similar problems occur 
and the recent EMA concept paper on extrapolation of efficacy and 
safety in medicine development6, proposes a general framework for 
adopting a scientific proof in a larger population, usually adults, to 
a much smaller population, usually children. Obviously, a similar 
problem is present for diseases with prevalences that vary by 
continent. For example, IgA nephropathy is rather rare in the EU but 
more frequent in Asia and Africa, so that one might be interested to 
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adopt proofs of efficacy from the larger populations to the 
EU population.
Recognizing that the performance of methodological 
tools appears to be rather unsatisfactory or not well 
understood with regard to validity, when the sample size 
deteriorates, in 2012 the EU announced the call ‘New 
methodologies for clinical trials for small population 
groups’ within the FP7 health innovation framework. 
The designated objective is to develop new or improved 
statistical methodologies for clinical trials aiming at the 
efficient assessment of the safety and/or efficacy of a 
treatment for small population groups in particular for 
rare diseases or personalised (stratified or individualised) 
medicine. The expected impact is to reduce design costs 
and deliver efficient clinical trials deriving reliable results 
from trials in small population groups.
In this paper we report the views of the IDeAl research 
consortium (www.ideal.rwth‐ aachen.de) concerning 
potential improvement of the design and analysis of 
clinical trials for small population with special interest 
in rare diseases. To set the scene, we start with a report 
about important aspects mentioned in selected recently 
published papers. We are not providing a systematic review 
about these aspects. Realizing that statistical methods for 
clinical trials in small populations are rather specific to 
the disease under consideration, a systematic review is 
infeasible. In the final section, we will comment on these 
methods and give some recommendations.
The landscape for small clinical trials
In what follows we will describe the most important 
practical aspects that affect the development of new 
methodologies for clinical trials in small population groups. 
Then we will give an overview on trial designs and analysis 
methods and end up with some more specific aspects.
Practical aspects for clinical trials in rare diseases
There is a growing pressure for (orphan) drug 
approvals to treat rare diseases from patients, health care 
bodies, governments etc. Based on the special situation 
with rare diseases there are some specific challenges. 
First, many rare diseases affect children with an unmet 
need for a therapy, there is a tendency to relax well 
established standards for treatment evaluation to bring 
new treatments faster to the patients. Second, since many 
rare diseases are supposed to be heterogeneous, it can 
be argued, that it is difficult to obtain a clinically relevant 
study population. Clinical parameters are difficult to define 
because many rare diseases are poorly characterized and 
under‐researched. This in particular refers to the difficulty 
of estimating the expected effect size of a therapy and to 
decide on the most appropriate duration of the study 
because of the limited knowledge about the natural cause 
of the disease7. Logistical problems are related to small 
number of patients and specialist centres7. The increasing 
number of “first in class” drugs8 causes reservation of 
some stakeholders based on limited knowledge of a new 
and unique mechanism for treatment of the disease. On the 
other hand, the estimated number of rare disease of 6000 
to 8000 is rapidly increasing, because improved diagnostics 
lead to more segmented diseases1.
Recruitment to a rare disease clinical trial is frequently 
mentioned as the major problem. In large or common 
clinical trials multicentre layouts, whether international 
or not, are often recommended to overcome recruitment 
problems. However, there are several practical challenges 
with international multicentre trials which are special 
with rare diseases like consensus among clinical experts 
and regulatory agencies about fundamental questions like 
uncertainties about the correct diagnosis in small centres 
and about consistency across centres, measurement 
of endpoints in cross cultural studies, etc.9 Although it 
is mentioned that the collaboration between sponsor, 
academia and regulatory agencies is the prime determinant 
of a trial’s success9, the patient perspective should not be 
underestimated. All of these groups should be involved 
in the early stage of the protocol development process, as 
they often are the best ones to define the relevant clinical 
endpoints, identify specialised centres and disseminate 
information about the study to the patients7. Furthermore, 
with many rare diseases well‐organised patient advocacy 
groups under a European umbrella participate in rare 
disease specific registries. This information is, however, 
currently rarely used for proof of efficacy. Further 
recruitment is prolonged because of geographically wide 
spread distribution and small number of patients within 
centres. New recruitment strategies different from the 
“if you build it they will come” idea cover aspects like a 
more active search of patients, most notably telephone 
reminders, open–trial designs and opt‐out strategies as 
well financial incentives are recommended10. Furthermore 
information on a patient’s home‐based care using modern 
methods of data capture, including electronic devices for 
continuous monitoring, such as iPads, may be helpful in 
overcoming recruitment problems11.
Design aspects for clinical trials in rare diseases
There is a considerable amount of information in 
rare diseases from observational studies. Although the 
number of 651 registries listed by the Orphanet report2 is 
small compared to the estimated 6000 to 8000 diseases, 
registries may serve as an important tool of information to 
study the natural history of a disease as well as to improve 
designing a clinical trial from various perspectives. These 
registries provide relatively large representative cohorts. 
Some authors recommend putting more emphasis on 
observational studies, like self‐ controlled observational 
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studies, case‐control studies and prospective inception 
cohort studies12. Registries can also serve as a basis for a 
randomized controlled trial13. Caution is necessary because 
it is argued that the high heterogeneity in phenotypic 
expression of many rare diseases may hinder optimal 
natural history and outcome studies based on registries14. 
However the same argument is frequently applied within 
the context of randomized clinical trials, e.g. by defining a 
suitable clinical population. Case‐control studies are useful 
for studying rare disease15. Applying this study type to 
rare disease registries matching techniques are found to 
minimize bias14.
Clinical trial designs with orphan drug approvals 
compared to non‐orphan drugs differ in various aspects. 
Most authors found that the pivotal studies for orphan 
drug approvals were more likely to be smaller, do not use 
placebo control, and use nonrandomized, un‐blinded trial 
design, e.g. single arm design and surrogate endpoints 
to assess efficacy16‐18. On the other hand, a survey in 
ClinicalTrials.gov shows, that Bayesian methods and 
adaptive randomisation, although recommended in the 
guideline are not used16.
To give some figure about “what is a small trial” one 
can refer to the 63 orphan drug approvals in the EU from 
2000 to 2010. Here 22 of 38 randomised controlled trials 
showing a total sample size below 5019. Given these figures, 
which suggest that the clinical trials are often small, one 
may question the relevance of the long run properties 
of randomization, the most important design technique 
to avoid bias in clinical trials. To address this the IDeAl 
consortium has developed methods to evaluate the impact 
of supposed bias type on the test decision, developed a 
selection bias corrected test and developed a software to 
evaluate and conduct a randomisation procedure20‐22. The 
next step is to publish a framework for choosing the best 
practice randomization procedure for a small clinical trial as 
well as the corresponding randomization‐based inference. 
This investigation should become a standard procedure, 
when designing a clinical trial, in particular a small one.
On the other hand, some argue to substitute the control 
group in a clinical trial by historical controls which, however, 
have been assessed as a non‐satisfactory solution23. Using 
external controls in clinical trials involves careful analysis 
and skilful adjustment24.
Adaptive designs have been proposed as a means 
of gaining efficiency in studying rare diseases25,26,12. A 
recent review27 showed that about 59% of adaptive 
designs evaluated by the scientific advice working party 
of the European Medicines Agency related to trials in rare 
diseases and about 36% applied for orphan designation. 
The most attractive adaptation is sample size reassessment 
based on interim data. Adaptive designs use accumulating 
data of an ongoing trial to decide how to modify design 
aspects without undermining the validity and integrity 
of the trial. Based on interim data a trial may be stopped 
for efficacy or futility like in group sequential designs. 
Especially adaptive seamless designs28,29 seem to be very 
attractive for rare diseases, where sample sizes lack to 
conduct a series of independent phase II and phase III 
trials. Adaptive seamless designs are the combination of 
a clinical phase II study (focusing on treatment selection, 
for example) with a phase III study (confirmatory testing 
of treatments) allowing treatment selection and sample 
size re‐assessment at a pre‐defined interim analysis. The 
IDeAl consortium showed that there is a huge inflation 
in the type 1 error rate if treatment selection and sample 
size reassessment are not addressed adequately in the 
design and analysis of such seamless trials30. There are 
also some caveats when the endpoint is survival31. The 
IDeAl consortium proposes to use modelling techniques 
like MCPMod32 within the framework of adaptive seamless 
designs to address these objectives in an efficient way. 
Furthermore adaptive designs have been proposed for 
population or endpoint selection, adaptive dose finding, 
e.g., with continual reassessment methods, or adapting 
the allocation process using either covariates or early 
observable outcomes, i.e. response adaptive randomization. 
Most techniques have extensively been evaluated with 
respect to large sample theory; but their validity has rarely 
been explored for small clinical trials. For instance, the 
attractive property of response adaptive randomization e.g. 
play the winner, drop the looser, Klein’s urn design etc. to 
allocate more patients to the more effective treatment have 
not been evaluated with respect to small samples. So from 
the practical point of view it has to be evaluated how many 
patients must be included in the trial to gain efficiency. 
The IDeAl consortium evaluates the gain in efficiency of 
response adaptive randomization techniques compared to 
parallel group designs and adaptive designs with a single 
interim analysis with respect to small samples.
Within patient designs including repeated measures, 
crossover, Latin Square, stepped wedge and n‐of‐1 design 
are expected to be applicable and more efficient than the 
traditional parallel group designs. Taking into account that 
many rare diseases are chronic conditions within‐ patient 
designs like crossover designs are promising12. However 
there are various limitations, e.g. carryover effects, which 
meant that caution is required in applying the design. 
Nevertheless, where applicable, such within‐patient 
studies can, not only bring considerable gains in efficiency, 
but also permit careful study of individual response to 
treatment, and one of the threads of the IDeAL project has 
been devoted to studying their potential.
Various claims have been made about superior designs 
from cross‐over trials allowing for carry‐over effects. 
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These claims should be treated with caution since the 
models involved are not very realistic. The example 
of a non‐linear dose response for a dose‐finding trial 
arranged in a Williams square is developed to show that 
if carry‐over is present to any appreciable degree the 
usual statistical models provide no guaranteed protection 
against its effects. It is concluded that the most reasonably 
defended assumption about carry‐over effects is that no 
important carry‐over has taken place and that, where this 
assumption cannot be defended, statistical models provide 
no satisfactory substitute for it33. Thus if the researcher can 
not exclude the existence of carryover effects a crossover 
design should not be considered. Similarly the selection 
of the stepped wedge design34, recommended because of 
ethical reasons and acceptance by the patients should be 
carefully considered. Here the variance of the simplest 
ABB/AAB stepped wedge design is 4 times the variance of 
the optimal crossover design ABB/BAA. Both cases might 
show the efficiency can be gained in practice and research 
should be aware of these results.
There are a lot of other designs with unknown efficiency 
with respect to small sample size like randomized 
withdrawal design, randomized placebo phase design, 
early escape design, delayed start design, re‐randomized 
designs35, dog leg design36, platform trials, basket designs 
and so on. Care should be given to uncritical application of 
such designs without any evaluation about the intended 
benefit.
Analysis aspects for clinical trials in rare diseases
Various recommendations concern the analysis of 
small clinical trials. The recommendation cover aspects to 
adjust the risk of erroneous decisions from clinical trials 
by carrying out low power clinical trials24 as well as accept 
greater type 1 error rate (10% onesided = 20% twosided)37. 
The suggestions may be contrasted to the ethical 
implications38 and the reliability of the study results39. 
Although the pressure in unmet clinical need scenarios in 
particular in rare diseases is high suggesting somewhat 
relaxed benefit risk assessment in particular by patients, 
the IDeAl consortium contrast these aspects with decision‐
theoretic arguments. The point is not only whether or not 
to relax the standard margins, but also to give a scientific 
basis as to how much relaxing is reasonable. Including all 
stakeholder perspectives, i.e. patients, regulators, industry, 
reimbursers and academics, for a tailored decision about 
the most efficient design and analysis approach, would be 
the scientific solution to the ideas mentioned above.
Some advocate as analytical strategies including exact 
procedure, hierarchical models, including modelling the 
pattern of “missingness”25. With respect to exact procedures, 
a first approach could be to think about nonparametric 
tests, like permutation tests40. The IDeAl consortium 
realizes that the usual approaches with population based 
inference is hard to justify in a limited population. The 
uncertainty of this approach is answered by considering 
randomization based inference. Within this context, the 
randomization based inference within hierarchical models 
is investigated as well. Further, the question about the 
evaluation of the natural cause of a disease is answered 
by the consortium with methods to analyse reliability in 
longitudinal small data sets.
A lot of discussions focus on the choice of endpoints. 
It seems to be specific to rare diseases, to switch to 
more patient relevant endpoints. There are initiatives 
to define and find relevant endpoints like COMET13,41 as 
well as disease specific initiatives, e.g. [www.treat‐ nmd.
eu/research/outcome‐measures/about/]. The effect of 
multiple endpoints as well as relevant effects in subscales 
need further investigation.
There is a broad consensus, that some benefit in the 
drug development program can be gained by surrogate 
endpoints in particular for rare diseases24,40,7. The problem 
with surrogate endpoints is, they may lack of clinical 
relevance, may not allow to measure the clinical benefit 
against adverse effects and their reliability is questionable. 
The IDeAl consortium develops a framework for validation 
of surrogate endpoints based on linear mixed‐effects and 
other hierarchical models, taking into account that there 
is less information available in the data than is usually the 
case. They also developed a framework for establishing 
reliability. This poses specific computational challenges.
Bayesian ideas are assessed to be helpful in various 
areas for therapy evaluation in rare diseases. There are 
two obvious purposes for which Bayesian methods can in 
principle be useful. The first is where different stakeholders 
have different utilities or prior beliefs. Incorporating these 
into a formal Bayesian analysis is a way of examining to 
what extent these impinge of potential decision‐making as 
a way of resolving possible conflicts. This was a key feature 
of the ‘Bayesian Approach to Randomised Trials, proposed 
over 20 years ago42. As already mentioned earlier, clinical 
decision making in rare cancers involving all stakeholders24 
is one aspect, where such Bayesian ideas are used.
The second use of Bayesian methods is as a technique 
for combining information from disparate sources, for 
example not only randomised clinical trials, but also 
registries and observational studies generally. For example, 
using Bayesian approaches as an analytical strategy25 [e.g. 
use hierarchical Bayesian meta‐analysis model to analyse 
combined results from n‐of‐1 trials13, designing clinical 
trials24,26 and to quantify resulting levels of information, 
and to incorporate external information37 is recommended. 
People increasingly want to be informed, empowered and 
engaged with their medical management, providing better 
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information to participants. This can be realized by patient 
centeredness in the design of clinical trials and use of 
Bayesian adaptive trials to adjust for changes in clinical 
practice in a prespecified manner26. The IDeAl consortium 
uses Bayesian ideas to design clinical trials adaptively, for 
extrapolation purposes43 and for clinical decision making.
Various aspects for clinical trials in rare diseases
There is considerable scope for improving drug 
development in rare diseases by using the promise 
of integrative mathematical analysis applied to 
pharmacokinetic‐pharmacodynamic models for selected 
drug candidates to optimize Phase III trial designs44. This 
implies the need for pharmacokinetic‐pharmacodynamics 
models as well as animal models for rare diseases. This is 
the point where “in silico” clinical trials start and may result 
in knowledge about the variability. The IDeAl consortium 
put emphasis on these questions by exploring non‐ linear 
mixed effects models as an important statistical tool to 
allow these aspects become available to better design small 
clinical trials. Further statistical methods for identification 
of interactions between the treatment and the genetic 
background are necessary for selecting groups of patients 
for personalized therapies as well as for identification of 
proper blocks of patients for randomized trials.
Another aspect which may be used to recommend 
new treatments for rare diseases is to use already existing 
knowledge so to avoid unnecessary clinical trials. This 
means to look for a drug, which is already in clinical 
use for a more common disease in case it is supposed 
to be efficacious within the rare disease as well45. This 
problem can be identified as an extrapolation. Here the 
dose‐response information is mentioned as a particular 
important topic in the analysis of small population groups6 
because by the transfer of knowledge from larger to 
smaller populations it is possible to obtain information 
in cases where much data is available and thus to avoid 
unnecessary studies. This is helpful e.g. if diseases are 
rare in the EU, like IgA nephropathy, but more common in 
other continents, like Africa or Asia. To apply therapeutic 
options, evaluated in larger populations could be one way 
to overcome the troubles with the conduct of a clinical trial 
in small population groups.
Expert Opinion
We have referred to various actual aspects of statistical 
methodologies for design and analysis of small clinical 
trials, which are present in the evaluation of new therapies 
in rare diseases. We have shown how the IDeAl project 
has been providing answers for many of the questions, 
however several specific questions have to be solved over 
time. The EMA’s interests like extrapolation, standards of 
evidence, data‐driven decision‐making, understanding 
value of research, multidisciplinary, simulations, effects, 
randomisation, bias and the use of historical data are 
addressed by IDeAl’s research. These aspects are treated 
within the 10 workpackages of the IDeAl project, which are 
depict in figure 146.
 
Figure 1: Exhibit of the IDeAl project broken down in the workpackages.
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Obverall, there are three levels which have to be 
addressed when considering small clinical trials.
At the first level, the rigorous application of already 
developed efficient design and analysis techniques is 
recommended. Using these methods can lead to application 
of techniques used in traditional clinical trials in smaller 
populations also. The benefit would be, that these techniques 
are in accordance with the regulatory and scientific 
guidelines and thus already accepted by all stakeholders. 
Within this context one can think about using optimal 
crossover designs, using ANCOVA models and avoiding 
analysis of percent change analysis, etc. At this level training 
about best methods and consultation forum for researchers 
and patients are most effective and necessary.
At the second level, evaluations of the traditional 
methods for design and analysis of clinical trials are 
necessary, to show the validity of these methods with 
respect to small sample sizes. Within this context, we need 
to understand e.g. when randomization fails to protect 
against bias, if linear mixed effects models are sensitive 
against imbalance, how reliable are interim data in an 
anyhow small clinical trial… With this in mind, all main 
stakeholders have to be well informed about, how “small” 
is “too small” and traditional methods fail.
And consequently at the third level, new methods should 
be developed for design and analysis of clinical trials where 
the traditional methods fail. The research of the IDeAl 
project is addressed in particular to level two and three. It 
is important not only to publish the research findings of the 
project in scientific journals. A strong mandate is to inform 
all relevant stakeholders through workshops, webinars 
etc about these methods and to train young scientist with 
these methods.
To give some more specific recommendations:
Randomization is one of the key features of clinical trials 
in drug development to minimize bias in clinical trials and 
consequently identify differences in the outcome variable by 
treatments alone. The argument is well accepted for larger 
trials but the less is known for smaller trials. Obviously, the 
question arises, which randomization procedure performs 
best for smaller clinical trials, and according to the ICH E6 
guideline, what is the appropriate analysis method. In rare 
diseases there are two types of bias which might affect the 
outcome, selection and chronological bias. Meanwhile our 
analysis indicates that they are working in an opposite 
direction. Depending on the amount of bias there is no 
unique choice of the best procedure, however an analysis 
of the performance could be made using the software tool 
randomizR. After conducting a trial according to a specified 
randomization procedure, the appropriate statistical test is 
a randomization test. The implementation of this test in the 
software is currently under work.
Biostatisticians have frequently and uncritically 
accepted the measurements provided by their medical 
colleagues engaged in clinical research. Such measures 
often involve considerable loss of information. Particularly 
unfortunate is the widespread use of the so‐called 
‘responder analysis,’ which may involve not only a loss of 
information through dichotomization, but also extravagant 
and unjustified causal inferences regarding individual 
treatment effects at the patient level, and, increasingly, 
the use of the so‐called number needed to treat scale of 
measurement. Other problems involve inefficient use of 
baseline measurements, the use of covariates measured 
after the start of treatment, the interpretation of titrations 
and composite response measures. Many of these bad 
practices are becoming enshrined in the regulatory 
guidance to the pharmaceutical industry. We consider the 
losses involved in inappropriate measures and suggest that 
statisticians should pay more attention to this aspect of 
their work47. 
It is well know that there is a considerable loss of 
information when continuous variables are dichotomised. 
In trials in common diseases, sample sizes are often greater 
than is necessary to provide proof of efficacy because trials 
are sized to prove safety and tolerability. Where this is the 
case, dichotomies, although still to be regretted, may not 
have a disastrous effect on the ability to prove efficacy. For 
rare diseases this will not be the case and such measures 
can and should be avoided48‐51. 
A regrettably common use of baseline measures is 
to construct so called change scores, or worse, calculate 
percentage change from baseline. The first does not make 
an efficient use of baselines and the second compounds 
this error by constructing a measure that has very poor 
distributional properties. There is scope for considerable 
gains in efficiency by using instead analysis of covariance 
(ANCOVA) fitting the baseline values or, where relative 
change is considered important, log transforming the 
baselines and outcomes prior to using ANCOVA49,52,53.
Especially when trials are small, considerable 
information can be gained by collecting measurements 
repeatedly over time. Moreover, such longitudinal profile 
allow the assessments of effect, largely based on within‐
patient changes, that otherwise could not be studied. Partial 
longitudinal profiles offer well‐known opportunities when 
patients drop out from therapy or from the study altogether, 
prior to the planned end of the study54. 
Stratification may or may not improve the efficiency of 
a trial by reducing the variance of the treatment effect. This 
is rather questionable, where the sample size is small and 
high unbalanced strata are to be expected. On the other 
hand, the argument for stratification is to reduce variance. 
This does not hold in general for rare diseases. 
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Adaptive interim analyses29 are another tool to improve 
the performance of clinical trials. However, the operating 
characteristics of potential adaptations should be carefully 
evaluated by clinical trial simulations beforehand. Especially 
adaptive seamless designs have a potential in small 
populations as they allow to tackle different objectives 
within a single trials using all (limited) data at hand. 
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